SCHEMBL6853318

SCHEMBL6853318

CCOc1ccc(C2C(C(=O)c3cc(OC)c(OC)c(OC)c3)C2(Cl)Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 2/20 0.48
MAPT P10636 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44
TUBA3C P0DPH7 2/20 0.44
TUBA1B P68363 2/20 0.44
TUBA4A P68366 2/20 0.44
TUBB4B P68371 2/20 0.44
TUBB3 Q13509 2/20 0.44
TUBB2A Q13885 2/20 0.44
TUBB8 Q3ZCM7 2/20 0.44
TUBA3E Q6PEY2 2/20 0.44
TUBA1A Q71U36 2/20 0.44
TUBA1C Q9BQE3 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7127073 0.89 TUBB1 (0.52) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL7124596 0.87 MAPT (0.49) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL6859785 0.82 KMT2A (0.49) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL7126392 0.81 LMNA (0.51) KMT2AMEN1POLBMAPTALDH1A1
SCHEMBL6859920 0.80 TUBB1 (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6858727 0.80 TUBB1 (0.40) MAPTALDH1A1LMNATUBB4ATUBB
SCHEMBL6860146 0.79 TUBB1 (0.52) SMN1; SMN2ALDH1A1LMNATUBB4ATUBB
SCHEMBL6315343 0.79 TUBB1 (0.41) SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6853132 0.78 TUBB1 (0.40) KMT2AMAPTALDH1A1LMNATUBB4A
SCHEMBL6321575 0.77 TUBB1 (0.41) SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453783-A1 SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS Aventis Pharma S.A. (FR) 2004-09-08 EP disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed
WO-2003048096-A1 SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS AVENTIS PHARMA S.A. (FR) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR KMT2A 877/4885MEN1 2077/4885POLB 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.